Exploring psychological resilience and demoralisation in prostate cancer survivors

Eur J Cancer Care (Engl). 2022 Nov;31(6):e13759. doi: 10.1111/ecc.13759. Epub 2022 Oct 21.

Abstract

Objective: This study aimed to investigate psychological resilience and demoralisation and their predictors and mediators in prostate cancer survivors (PCSs).

Methods: A cross-sectional research design was used. PCSs (N = 122; mean time since diagnosis = 54.79 months, range in 13 years and 2 months) were recruited using convenience sampling at the outpatient department of a hospital in Taiwan. Data collection was conducted using self-report structured questionnaires, including one for demographic and disease characteristics, the Expanded Prostate Cancer Index Composite, Cancer Survivors' Self-Efficacy Scale, Connor-Davidson Resilience Scale and the Demoralisation Scale.

Results: In PCSs, a lower most-recent level of prostate-specific antigen and higher cancer-specific self-efficacy were associated with better psychological resilience. Further, fewer hormonal, bowel and urinary symptoms and bother; higher cancer-specific self-efficacy; and better psychological resilience were associated with less demoralisation. Cancer-specific self-efficacy was a mediator for the relationship between urinary symptoms and bother and demoralisation, while psychological resilience mediated the relationship between cancer-specific self-efficacy and demoralisation.

Conclusions: The results reveal that cancer-specific self-efficacy is a protective factor against demoralisation and increases psychological resilience in PCSs. Better psychological resilience and fewer physical symptoms and bother are associated with less demoralisation in PCSs.

Keywords: demoralisation; prostate cancer; resilience; self-efficacy; self-management.

MeSH terms

  • Adaptation, Psychological
  • Cancer Survivors*
  • Cross-Sectional Studies
  • Humans
  • Male
  • Prostate
  • Prostatic Neoplasms*
  • Resilience, Psychological*
  • Surveys and Questionnaires